OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a report released on Friday. The firm set a “sell” rating on the medical research company’s stock.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of OpGen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 5th. Alliance Global Partners lowered their target price on shares of OpGen from $4.35 to $3.00 in a research note on Wednesday, January 12th.

NASDAQ:OPGN opened at $0.76 on Friday. The company has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $1.26. The company has a market cap of $35.38 million, a price-to-earnings ratio of -0.63 and a beta of -0.74. The company has a quick ratio of 1.93, a current ratio of 2.00 and a debt-to-equity ratio of 0.17. OpGen has a 52 week low of $0.67 and a 52 week high of $3.72.

OpGen (NASDAQ:OPGN – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The medical research company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.19). The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.40 million. OpGen had a negative return on equity of 71.61% and a negative net margin of 810.33%. During the same quarter last year, the firm earned ($0.35) EPS. On average, analysts expect that OpGen will post -0.62 EPS for the current year.

Several hedge funds have recently modified their holdings of OPGN. Millennium Management LLC acquired a new position in shares of OpGen during the second quarter worth $80,000. Geode Capital Management LLC lifted its position in OpGen by 10.3% in the third quarter. Geode Capital Management LLC now owns 353,208 shares of the medical research company’s stock valued at $1,017,000 after acquiring an additional 32,875 shares during the last quarter. Renaissance Technologies LLC lifted its position in OpGen by 74.6% in the third quarter. Renaissance Technologies LLC now owns 151,500 shares of the medical research company’s stock valued at $436,000 after acquiring an additional 64,747 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in OpGen in the third quarter valued at $154,000. Finally, Marshall Wace LLP purchased a new stake in OpGen in the third quarter valued at $744,000. Hedge funds and other institutional investors own 7.74% of the company’s stock.

OpGen Company Profile (Get Rating)

OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs).

Featured Stories